Press Release – Anscombe Centre Welcomes End of Puberty Blocker Use for Children Experiencing Gender Dysphoria

Read in PDF

The Anscombe Bioethics Centre welcomes the decision of NHS England to end the use of puberty blockers for children with gender dysphoria outside of the context of a clinical trial. In the view of the Centre, many of the reasons that make this approach to gender dysphoria in minors inappropriate would apply equally to their use as part of a clinical trial. Nevertheless, the suspension of the routine prescription of these drugs for this purpose is certainly a welcome move.

This decision by NHS England brings clinical practice for gender dysphoria in minors closer to that already advocated by the Centre in 2017. At that time, the Director of the Centre, Professor David Albert Jones, stated that:

One area where hormone therapy should have no place is in the treatment of children with gender incongruent feelings or suspected gender dysphoria. It is widely accepted that, in most instances, such feelings do not persist into adulthood. Furthermore, minors are not well placed to give informed consent to interventions that could affect their long-term sexual and reproductive health.

Gender identity clinics in the NHS do not prescribe cross-hormone therapy in minors but they sometimes prescribe hormone analogues to suppress puberty. The aim is to delay potentially distressing physical changes caused by their body becoming even more like that of their biological sex and hence to delay decisions about more drastic measures until the child reaches adulthood. However, while often turbulent and always challenging, puberty is a healthy part of physical and emotional development. Suppressing puberty is a drastic intervention. It deprives someone of an important stage of personal development and begs the question as to the person’s mature identity.

The best approach to the treatment of minors with gender dysphoria is for them to receive support to help them cope with the emotional distress of the condition, without rushing into more drastic treatments. In practice, the ethics of this approach will depend crucially on the nature of the support that is provided. The first option for psychological support should involve the whole family.”

END

Notes to Editors:

Most recent

Euthanasia & Assisted Suicide (EAS)

Press Statement – Support for Assisted Suicide Ebbs Away in Scotland

16 April 2024

The Journal of Medical Ethics Forum has released an article by Prof. David Albert Jones, Director of...

Embryo Research

Director Gives Presentation to the Babraham Institute on Embryo Research

10 April 2024

Recently our Director, Professor David Albert Jones, provided a presentation to the Babraham Institu...

Euthanasia & Assisted Suicide (EAS)

Press Statement – A Further Warning From Oregon: More Assisted Suicides, More Bad Deaths

22 March 2024

This week, Oregon produced its twenty-sixth ‘Death With Dignity Act’ Report. This shows that 2023 sa...

Support Us

The Anscombe Bioethics Centre is supported by the Catholic Church in England and Wales, Scotland, and Ireland, but has also always relied on donations from generous individuals, friends and benefactors.

FIND OUT MORE MAKE A DONATION